Specific antibodies or inhibitors that neutralizing CD68 in the TME in there cancers might provide a new direction for tumor immunotherapy, especially targeting these immune cells that significantly associated with CD68 expression, such as B cells, CD4+ and CD8+ T cells, dendritic cells, macrophages, and neutrophils. This evidence concerns the gene CD4 and cancer.